Federated Investors Inc. PA reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 6.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,786 shares of the medical research company’s stock after selling 667 shares during the period. Federated Investors Inc. PA’s holdings in Bio-Rad Laboratories were worth $2,215,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board purchased a new position in Bio-Rad Laboratories in the 2nd quarter worth about $113,000. Advisory Services Network LLC purchased a new position in Bio-Rad Laboratories in the 1st quarter worth about $115,000. Flinton Capital Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the 1st quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after purchasing an additional 96 shares in the last quarter. Turner Investments LLC purchased a new position in Bio-Rad Laboratories in the 2nd quarter worth about $136,000. Finally, Meadow Creek Investment Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the 1st quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock worth $175,000 after purchasing an additional 132 shares in the last quarter. 62.85% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on BIO shares. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the stock from $220.00 to $195.00 in a research note on Wednesday, June 28th. Zacks Investment Research cut Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. Finally, TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Bio-Rad Laboratories has an average rating of “Buy” and a consensus price target of $228.80.

Bio-Rad Laboratories, Inc. (NYSE BIO) opened at 218.42 on Friday. Bio-Rad Laboratories, Inc. has a 52 week low of $154.70 and a 52 week high of $242.79. The stock has a market cap of $6.47 billion, a PE ratio of 431.66 and a beta of 0.93. The company has a 50-day moving average price of $223.06 and a 200-day moving average price of $216.05.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/09/bio-rad-laboratories-inc-bio-shares-sold-by-federated-investors-inc-pa.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.